Hevascol

Hevascol is a prescription‑only iodinated contrast agent whose active ingredient is ethyl esters of iodised fatty acids derived from poppyseed oil. The product is supplied as an injectable preparation for intra‑arterial, intralymphatic, and intrauterine administration; specific strength and dosage form are not publicly disclosed. It is marketed in the European Union to enhance the visibility of vascular and lymphatic structures during clinical diagnostic radiographic examinations.

Hevascol is employed as an iodinated contrast medium in several radiographic procedures that require enhanced visualization of internal structures.

- Intra‑arterial angiography to delineate arterial anatomy and detect stenoses or occlusions. - Intralymphatic lymphography for mapping lymphatic vessels and identifying leaks or blockages. - Intrauterine hysterosalpingography to assess uterine cavity shape and tubal patency. - Peripheral vascular imaging to evaluate limb perfusion and collateral circulation. - Interventional radiology guidance during embolization or stent placement procedures. - Pre‑procedural imaging in surgical planning where detailed vascular detail is required.

Adverse reactions to Hevascol are generally related to its iodine content and the injectable vehicle; they can range from mild, transient events to rare serious complications.

Common: - Transient warmth or flushing sensation at the injection site. - Mild nausea or vomiting shortly after administration. - Headache or dizziness occurring within minutes. - Temporary urticaria or mild skin itching. - Mild transient metallic taste in the mouth. - Temporary increase in serum iodine levels without clinical effect.

Serious: - Acute hypersensitivity reactions, including bronchospasm or anaphylaxis. - Severe renal impairment or contrast‑induced nephropathy. - Cardiovascular instability such as hypotension or arrhythmia. - Pulmonary edema or severe respiratory distress. - Thromboembolic events related to intravascular injection. - Severe allergic skin reactions such as Stevens‑Johnson syndrome (rare).

When using Hevascol, clinicians should assess patient risk factors and follow specific safety measures to minimize potential adverse events.

- Verify absence of known iodine or poppyseed oil allergy before administration. - Evaluate renal function; avoid use in patients with severe impairment or recent contrast exposure. - Ensure adequate hydration before and after the procedure to support renal clearance. - Use the lowest effective dose and limit injection rate to reduce discomfort. - Monitor vital signs and for signs of hypersensitivity during and after injection. - Consider alternative imaging modalities for pregnant or breastfeeding individuals. - Document any previous contrast reactions in the patient’s medical record.

Hevascol may interact with other agents that affect renal function, iodine metabolism, or hypersensitivity risk; awareness of these interactions helps guide safe use.

Avoid: - Concurrent use of high‑dose nephrotoxic drugs such as aminoglycosides or amphotericin B. - Administration of other iodinated contrast media within 24 hours. - Use with radiopharmaceuticals that rely on iodine uptake for diagnostic purposes.

Use with caution: - Loop diuretics, which may exacerbate contrast‑induced nephropathy; ensure adequate hydration. - Beta‑blockers, as they can mask early signs of anaphylaxis. - ACE inhibitors or ARBs, which may increase risk of renal impairment when combined with contrast. - Antihistamines, which may mask early allergic symptoms but do not prevent severe reactions.